Also, treatment with Salbutamol, a β-adrenergic agonist with an impact on NMJ, showed beneficial outcomes in SMA patients [12, 13], however, this may result from the known impact of Salbutamol on SMN protein stability and turnover [14–16]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.